U.S. Appln. Serial No.: 10/569,812

Group Art Unit: 1621

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

- 1. (Cancelled).
- 2. (Cancelled).
- 3. (Cancelled).
- 4. **(Currently Amended)** A compound according to claim **4 11**, wherein Z represents a bond or O.
- 5. (Currently Amended) A compound according to claim 4 11 of formula (Ia):

$$\mathbb{R}^{13} \qquad \qquad (Ia)$$

wherein:

 R^{13} is H, halo, CF_3 , -OCF₃, cyano, nitro, OR^{14} , SR^{15} or COR^{16} ; and R^{14} , R^{15} , R^{16} independently are H, C_{1-6} alkyl or C_{1-4} alkylaryl; or physiologically functional derivatives thereof.

- 6. (Cancelled).
- 7. (Cancelled).
- 8. (Cancelled).
- 9. **(Currently Amended)** A pharmaceutical composition comprising a compound according to claim 4 11 and a pharmaceutically acceptable carrier.

U.S. Appln. Serial No.: 10/569,812

Group Art Unit: 1621

10. **(Currently Amended)** A process for preparation of compounds of formula (I) as defined in claim **4 11**, wherein the process comprises:

(A) preparing a compound of formula (I), wherein Z is a bond and R¹ is an optionally substituted 5- or 6- membered aryl or heteroaryl, by reacting a compound of formula (II):

$$L^{1}$$
 Q R^{2} (II)

wherein R², Q and X are as previously defined for formula (I) and L¹ is a leaving group, with a reagent suitable to introduce the group R¹; or

(B) (i) preparing a compound of formula (I), wherein Z is O, S, SO, SO₂, NR⁴ or OCR⁴R⁵, by reacting a compound of formula (III):

$$X = \begin{pmatrix} X & & \\ & & \\ & & \end{pmatrix}$$

wherein R², Q and X are as previously defined for formula (I) and Y is OH, SH, NHR⁴ or HOCR⁴R⁵, with a compound of formula (IV):

$$R^1L^2$$
 (IV)

wherein R¹ is defined above for compounds of formula (I) and L² represents a leaving group; and

- (ii) wherein Y is -SH, optionally followed by oxidizing the Y group to the corresponding SO or SO₂ group as required; or
- (C) preparing a compound of formula (I), wherein Z is -CR⁴R⁵O-, by reacting a compound of formula (III), wherein Y is -OH, with a compound of formula (V):

$$R^1CR^4R^5L^3$$
 (V)

wherein R¹ R⁴, R⁵ are defined above for compounds of formula (I) and L³ represents a leaving group; or

- (D) preparing a compound of formula (I), wherein Z is CH_2 and R^1 is an optionally substituted 5- or 6- membered aryl or heteroaryl, by reacting
 - (i) a compound of formula (VI):

U.S. Appln. Serial No.: 10/569,812 Group Art Unit: 1621

$$H \xrightarrow{Q} R^2 \qquad (VI)$$

wherein Q, X and R² are as defined above, with an optionally substituted 5- or 6-membered aryl or heteroaryl nucleophile, which is a compound of formula (VII):

wherein A is a 5- or 6- membered aryl or heteroaryl, R¹⁷ is H or one or more substituents and M is a metal and

- (ii) reducing and eliminating a resultant or product alcohol formed form step (i); and,
- (E) optionally deprotecting compounds of formula (I) with a protecting group.

11. (New) A compound of formula (I):

$$R^1$$
— Z — Q
 R^2
 (I)

wherein:

 R^1 is optionally substituted -C₄₋₁₂ alkyl, -C₂₋₁₀alkylcycloalkyl, -C₂₋₆alkylheterocycloalkyl,

-C₂₋₆alkylaryl, optionally substituted 5- or 6-membered aryl or heteroaryl, provided that R¹ is not pyridinyl;

Z is a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵ or CR⁴R⁵O; or Z, R¹ and Q together form an optionally substituted fused tricyclic group;

Q is unsubstituted phenyl;

X is COOH;

R² is CONH₂;

 R^4 and R^5 each independently is H, C_{1-6} alkyl or C_{1-4} alkylaryl; or physiologically functional derivatives thereof; and further provided that when R^1 is C_{4-12} alkyl, Z is other than a bond, O or CH_2 .